Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 50 - ASPIK aspirin vs placebo in resected PI3K-mutated colon cancer
2016-002209-20Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colon adenocarcinoma comparing Aspirin with Placebo (2 arms). Primary endpoint: Disease-free survival at 3 years. Started Nov 2016; status: active.
02
Drugs
aspirin
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on 2016-002209-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002209-20.